Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $223000.0.

  • X4 Pharmaceuticals' Depreciation & Amortization (CF) fell 1647.94% to $223000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 12683.76%. This contributed to the annual value of $796000.0 for FY2024, which is 8997.61% up from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Depreciation & Amortization (CF) is $223000.0, which was down 1647.94% from $355000.0 recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $476000.0 in Q1 2025 and a low of $62000.0 during Q4 2023
  • Its 5-year average for Depreciation & Amortization (CF) is $172684.2, with a median of $132000.0 in 2021.
  • In the last 5 years, X4 Pharmaceuticals' Depreciation & Amortization (CF) tumbled by 5118.11% in 2024 and then surged by 66774.19% in 2025.
  • Quarter analysis of 5 years shows X4 Pharmaceuticals' Depreciation & Amortization (CF) stood at $132000.0 in 2021, then fell by 6.06% to $124000.0 in 2022, then tumbled by 50.0% to $62000.0 in 2023, then surged by 340.32% to $273000.0 in 2024, then decreased by 18.32% to $223000.0 in 2025.
  • Its last three reported values are $223000.0 in Q3 2025, $355000.0 for Q2 2025, and $476000.0 during Q1 2025.